BEVACIREL 100MG INJECTION contains Bevacizumab, which belongs to the group of medicines called Antineoplastic agents. It is used in adult patients with fluoropyrimidine (a chemotherapy medicine) to manage metastatic cancer in the large bowel (colon or rectum). It is also used with Paclitaxel or Capecitabine (chemotherapy medicine) to manage metastatic breast cancer in adult patients.
BEVACIREL 100MG INJECTION is used with a chemotherapy regimen containing platinum to manage advanced non-small cell lung cancer without epidermal growth factor receptor (a mutated protein responsible for causing cancer in a cell) and with Erlotinib (a chemotherapy medicine) to manage metastatic non-small cell lung cancer with epidermal growth factor receptor (in cancer cells) in adult patients.
This medicine is indicated for use to manage metastatic kidney cancer along with interferon (chemotherapy medicine), which is also indicated for use with carboplatin, gemcitabine, and/or carboplatin and Paclitaxel (chemotherapy medicine) to manage recurrent advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients.
This medicine is also used to manage persistent, recurrent, or metastatic cervical cancer with or without Paclitaxel, Cisplatin, or Paclitaxel and Topotecan in adult patients. BEVACIREL 100MG INJECTION is not recommended for use in patients allergic to Bevacizumab, Chinese hamster ovary (CHO) cell products, and/or other recombinant human or humanized antibodies. It is also not recommended for use in patients who have recently undergone major operations or surgery.
Before receiving BEVACIREL 100MG INJECTION, inform your doctor if you are scheduled for an invasive dental treatment or surgery and/or suffer from conditions such as inflammation inside the abdomen, uncontrolled high blood pressure, dental problems, kidney problems, and liver problems (such as hepatic injury).
BEVACIREL 100MG INJECTION is not recommended for use in pregnant women or in women planning for pregnancy since it may cause harm to the unborn baby. It is also not recommended for use by breast-feeding women since it may interfere with the growth and development of the baby.
BEVACIREL 100MG INJECTION is not recommended for use in children and adolescents (aged below 18 years) since the safety and efficacy of the medicine are not established in this age group. It is advised to be used with caution in elderly patients (aged 65 years and older) after consulting the doctor.
The most common side effects of receiving BEVACIREL 100MG INJECTION are constipation, loss of appetite, fever, eye problems (such as an increase in the production of tears), changes in speech or sense of taste, runny nose, and/or loss of body weight. Consult your doctor if any of these symptoms worsen.
To manage:
BEVACIREL 100MG INJECTION works by reducing microvascular growth of tumour blood vessels which leads to reduced blood flow to the tumour cells resulting in its death thus treating the disease and preventing its spread to other parts of the body in affected individuals.
BEVACIREL 100MG INJECTION will be given to you only by a doctor or a nurse into a vein as an intravenous infusion. Your doctor will determine the correct dose and duration for you based upon your age, body weight, and disease condition.
Stop receiving BEVACIREL 100MG INJECTION and contact your doctor immediately if you experience any of the following side effects:
Try to eat high-fiber foods such as vegetables, cereals, and fresh fruit, and drink plenty of water. Involve yourself in regular exercise (going for a daily walk or run), and if this does not help, consult and inform your doctor about receiving alternate treatments for constipation.
Try moisturizing your skin with an ointment, cream, or lotion 2 or 3 times a day, or as often as needed. Moisturizers help to keep the area moist, so they work best on damp skin. After you bathe, pat your skin dry, then apply your moisturizer. Try to avoid using skin care products and soaps that contain alcohol, fragrances, dyes, or other chemicals.
BEVACIREL 100MG INJECTION is not recommended for use in pregnant women or in women planning for pregnancy since it may cause harm to the unborn baby. Women of childbearing potential should use effective contraceptives during and after stopping treatment with medicine for the next 6 months to prevent accidental pregnancy. If pregnancy occurs during treatment with BEVACIREL 100MG INJECTION, then you should inform your doctor immediately. Consult your doctor before receiving the medicine.
BEVACIREL 100MG INJECTION is not recommended for use in breast-feeding women during and for the next 6 months of therapy after stopping the medicine since it may interfere with the growth and development of your baby. Consult your doctor before receiving the medicine.
Do not drive or operate machines if you experience sleepiness or fainting after receiving the medicine.
Do not receive BEVACIREL 100MG INJECTION if you are allergic to Bevacizumab, Chinese hamster ovary (CHO) cell products, other recombinant human or humanized antibodies, and/or any other ingredients of this medicine.
BEVACIREL 100MG INJECTION should be used with caution in patients with heart problems such as heart attack and stroke. Consult your doctor before receiving the medicine.
BEVACIREL 100MG INJECTION is not recommended for use in children and adolescents (aged below 18 years) since the safety and efficacy of the use of medicine are not established in this age group. Consult your doctor before receiving the medicine.
BEVACIREL 100MG INJECTION should be used with caution in elderly patients (aged 65 years and above). Consult your doctor before receiving the medicine.
BEVACIREL 100MG INJECTION is not recommended for use if you:
Before receiving BEVACIREL 100MG INJECTION, inform your doctor if you:
A. Drug-Drug interactions:
Before receiving BEVACIREL 100MG INJECTION, inform your doctor if you are receiving any of the following medicines:
Overdosage:
BEVACIREL 100MG INJECTION will be administered to you only by a doctor or a nurse in a hospital, and so it is unlikely to receive an overdose. However, consult your doctor or nurse if you experience any unusual symptoms.
Drug | : | Bevacizumab |
Pharmacological Category | : | Antineoplastics |
Therapeutic Indication | : | Metastatic cancer in the large bowel (colon/rectum), breast, and kidney, Advanced non-small cell lung cancer, Recurrent advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer and Persistent, recurrent, or metastatic cervical cancer |
Dosage Forms | : | Injection |
Q: What is BEVACIREL 100MG INJECTION used for?
A: BEVACIREL 100MG INJECTION is used in adult patients to manage metastatic cancer in the large bowel (colon/rectum), breast, kidney, and lungs. It is also used to manage recurrent advanced epithelial ovarian, fallopian tube/primary peritoneal cancer, and/or persistent, recurrent, or metastatic cervical cancer in affected individuals.
Q: How does BEVACIREL 100MG INJECTION work?
A: BEVACIREL 100MG INJECTION works by reducing microvascular growth of tumour blood vessels which leads to reduced blood flow to the tumour cells resulting in its death thus treating the disease and preventing its spread to other parts of the body in affected individuals.
Q: What are the common side effects of receiving BEVACIREL 100MG INJECTION?
A: The most common side effects of receiving BEVACIREL 100MG INJECTION are constipation, loss of appetite, fever, eye problems (such as an increase in the production of tears), changes in speech or sense of taste, runny nose, and/or loss of body weight. Consult your doctor if any of these symptoms worsen.
Q: How is BEVACIREL 100MG INJECTION administered?
A: BEVACIREL 100MG INJECTION will be given to you only by a doctor or a nurse into a vein as an intravenous infusion. Your doctor will determine the correct dose and duration for you based upon your age, body weight, and disease condition.
Q: Can BEVACIREL 100MG INJECTION be administered to pregnant and breastfeeding women?
A: No, BEVACIREL 100MG INJECTION is not recommended for use in pregnant women or in women planning for pregnancy since it may cause harm to the unborn baby. It is also not recommended for use by breast-feeding women since it may interfere with the growth and development of the baby. Consult your doctor before receiving the medicine.
1. KD Tripathi MD. Anticancer Drugs. Essentials of Medical Pharmacology 8th edition. 2019. Page- 930.
2. Filis Kazazi-Hyseni, Jos H. Beijnen, Jan H. M. Schellen. Bevacizumab. NIH National Library of Medicine. National Center for Biotechnology Information. PMC PubMed Central. August 2010. [Accessed on 30th January 2023] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228024/
3. Pfizer Ireland Pharmaceuticals. Electronic Medicines Compendium (EMC). [Revised in January 2023] [Accessed on 30thJanuary 2023] https://www.medicines.org.uk/emc/files/pil.13267.pdf
Written By Dr. N. Sai Swaroop, Pharm.D
Last updated on 27 Nov 2023 | 04:42 PM(IST)
Additional Discount on this product
Please get a call back from our expert
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.